Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 AUG 3 ... PharmFilm technology. Through our strategic partnerships and recent NDA submission for ondansetron orally dissolving thin film, we have validated our thin film platform and its potential ...
2009 OCT 19 ... (25 mg/m(2), 30 minutes infusion) on days 1, 8, and 15, every 4 weeks for 4 to 6 cycles. Ondansetron (8 mg) and dexamethasone (8 mg) were given intravenously before chemotherapy. The ...
2009 AUG 18 ... practiced on a battery of computerized performance tests until their results stabilized. Ondansetron 8 mg or placebo was administered 2 h before sailing aboard a 500-ton naval vessel in ...
2009 NOV 16 ... changes in these molecular substrates have a bearing on the pharmacological effects of ondansetron and pregabalin in OA. Osteoarthritis was induced via intra-articular injection of ...
2009 NOV 16 ... Following the development of the first generation 5-HT3 receptor antagonists, such as ondansetron and granisetron, in the late '80s and early '90s, in recent years new compounds have ...
2009 NOV 16 ... randomly assigned among six treatment arms. The primary analysis compared a control arm [ondansetron/dexamethasone (Ond/Dex)] with three investigational treatments (Ond/Dex plus oral ...
2009 AUG 25 ... specific isocratic RP-LC-UV method was developed and validated for the determination of ondansetron in pharmaceutical dosage forms of orally disintegrating tablets, oral solution and ...
2009 NOV 1 ... ramosetron for the prevention of postoperative nausea and vomiting (PONV) with that of ondansetron or placebo in high-risk patients undergoing gynaecological surgery," investigators in ...
2009 SEP 7 ... and ketorolac (30 mg IV). Antiemetic prophylaxis consisted of a combination of ondansetron (4 mg), 0 dexamethasone (4 mg), and metoclopramide (10 mg) at the end Of surgery. ...
2009 JUL 27 ... in an animal model of neuropathic pain. Co-administration of WAY100635, ketanserin or ondansetron with paroxetine induced no significant change in the antiallodynic effect of paroxetine. ...
2009 JUN 29 ... with the occurrence of emesis. Pretreatment with the 5-HT3-receptor antagonist ondansetron (2 mg/kg, i.p.) inhibited both the emesis and the increased glutamate levels," wrote K. ...
2009 NOV 2 ... moderate inhibitor of CYP3A), dexamethasone (a substrate and weak inducer of CYP3A), and ondansetron (a mixed CYP substrate) were evaluated in a two-part, three-period, single-sequence ...
2009 JUL 21 ... "The objective of this investigation was to prepare orodispersible tablets (ODTs) of ondansetron HCl using a direct compression method. A combination of glycine and chitosan was used as ...
2009 JUL 27 ... Following the development of the first generation 5-HT3 receptor antagonists, such as ondansetron and granisetron, in the late '80s and early '90s, in the recent years new compounds ...
2009 JUL 6 ... Following the development of the first generation 5-HT3 receptor antagonists, such as ondansetron and granisetron, in the late '80s and early '90s, in the recent years new ...
2009 JUL 27 ... placebo-controlled trial to assess whether a three-drug antiemetic regimen of ondansetron, dexamethasone, and the neurokinin-1-receptor antagonist casopitant mesylate was able to ...
2009 AUG 10 ... "The effect of central administration of ondansetron, a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist on gastric secretion and gastric ...
2009 AUG 17 ... distressing complications after neurosurgical procedures. We evaluated the efficacy of ondansetron and granisetron to prevent PONV after supratentorial craniotomy." "In a ...
